Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?
Etsuko
E
Hashimoto
Geoffrey C
GC
Farrell
D054392:Adipokines; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D000071451:Chitinase-3-Like Protein 1; D018450:Disease Progression; D005234:Fatty Liver / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D053538:Keratin-18 / Q000097:blood*; D037102:Lectins; D008099:Liver / Q000000981:diagnostic imaging / Q000473:pathology*; D008103:Liver Cirrhosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology; D011237:Predictive Value of Tests; D012372:ROC Curve; D011859:Radiography; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood
D054392:Adipokines; D015415:Biomarkers; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D006023:Glycoproteins; C488421:KRT18 protein, human; D053538:Keratin-18; D037102:Lectins; D019715:Tissue Inhibitor of Metalloproteinase-1; D006820:Hyaluronic Acid